marijuana stocks news

Vertical Designs Terminates Abbatis Licence

VANCOUVER, Dec. 30, 2014 /CNW/ – Vertical Designs Ltd. (“Vertical Designs”, “VDL” or the “Company”) announced today that they have issued notice of termination of the License Agreement dated December 12, 2012 with Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT), on the grounds of material breach of the Licence Agreement by Abbatis.  The termination of the License Agreement is effective immediately.

Abbatis has been instructed that all Confidential materials (as that term is defined in the License Agreement) must be returned to VDL offices.

About Vertical Designs Inc.

Vertical Designs Ltd. of Vancouver, B.C. is a privately owned company that designs and builds innovative, fully sustainable and complete vertical growing solutions. VDL is capable of producing local, truly nutritious, safe, secure, environmentally friendly and low (total) cost food crops year-round. Its proprietary technologies control precise combinations of light, temperature, water, and nutrients to create specific growing conditions that result in optimum crop production, product quality and shelf- life. Vertical Designs systems can be used to produce leafy greens vegetables like lettuce, spinach and herbs as well as plants that require pollination such as strawberries.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Curaleaf Holdings, Inc. (CURLF) Expands “The Farmer’s Select” Program In Partnership with Autumn Brands

Curaleaf’s Select Brand Expands “The Farmer’s Select” Program In Partnership with Autumn…

$PMCB Releases Corporate Video

PharmaCyte Biotech Releases Corporate Video PharmaCyte Biotech, Inc. (PMCB), a clinical stage…

 Charlotte’s Web Holdings, Inc. (CWBHF) to Acquire Abacus Health Products

Charlotte’s Web to Acquire Abacus Health Products for Combined 35% Marketshare of…

GW Pharmaceuticals (GWPH) Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019

– Epidiolex U.S. Q2 net sales of $68.4 million – – Positive…